Cannibinoid

As Canada prepared for full legalization of weed and the cannabis industry in the United States was booming, more businesses joined the industry either as startups or as established companies that changed or diversified their business models. For publicly traded companies, announcing entry into...

Elemer Piros of Cantor Fitzgerald maintained an Overweight rating and $208 price target on GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) after the developer of cannbinoid products reported its fiscal second-quarter results. Piros' main takeaway from the report and conference call is that GW...